比美吉珠单抗作为附加疗法治疗对 certolizumab pegol 应答不佳的类风湿关节炎:概念验证研究
这项 2a 期双盲概念验证研究纳入中重度类风湿关节炎患者,先开放标签使用 certolizumab pegol(CZP),第 8 周应答不佳者随机接受 CZP 联合比美吉珠单抗或 CZP 联合安慰剂。第 20 周时联合比美吉珠单抗组 DAS28(CRP) 下降更大(后验概率 99.4%),但治疗中出现的不良事件发生率更高。
要点
- 对 CZP 应答不佳的 RA 患者,加用比美吉珠单抗可更显著降低 DAS28(CRP)。
- 联合比美吉珠单抗组感染和侵染类 TEAE 发生率为 50.0%,高于安慰剂组的 22.2%。
- 双靶向 IL-17A 和 IL-17F 未发现意外或新的安全性信号,但 TEAE 发生率更高。
核心结论
- 在 CZP 应答不佳的 RA 患者中,加用比美吉珠单抗可快速降低疾病活动度,概念验证得到确认。
- 同时中和 IL-17A 和 IL-17F 未发现意外或新的安全性信号,但 TEAE 发生率更高。
研究设计与样本
- 2a 期、双盲、概念验证研究(NCT02430909)。
- 中重度 RA 患者先开放标签接受 CZP 400 mg(第 0、2、4 周)和 200 mg(第 6 周)。
- 第 8 周 DAS28(CRP)>3.2 的应答不佳者按 2:1 随机接受 CZP 200 mg 每 2 周联合比美吉珠单抗(240 mg 负荷剂量后 120 mg 每 2 周)或 CZP 联合安慰剂。
- 共入组 159 例患者,其中 79 例第 8 周应答不佳并随机分组:联合比美吉珠单抗组 52 例,联合安慰剂组 27 例。
主要发现
- 第 20 周时,联合比美吉珠单抗组 DAS28(CRP) 较基线的下降大于联合安慰剂组(后验概率 99.4%)。
- 最常见的 TEAE 为感染和侵染:联合比美吉珠单抗组 50.0%(26/52),联合安慰剂组 22.2%(6/27)。
关键数值与推荐
- 第 8 周应答不佳定义为 DAS28(CRP)>3.2。
- 主要疗效变量为第 8 周至第 20 周 DAS28(CRP) 的变化。
- 主要安全性变量为治疗中出现的不良事件(TEAE)发生率。
临床怎么用
- 对 CZP 应答不佳的 RA 患者,加用比美吉珠单抗可能进一步降低疾病活动度。
- 联合治疗时需关注感染和侵染类不良事件的发生率升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol. METHODS: During this phase 2a, double-blind, proof-of-concept (PoC) study (NCT02430909), patients with moderate-to-severe RA received open-label CZP 400 mg at Weeks 0, 2 and 4, and 200 mg at Week 6. Patients with IR at Week 8 (Disease Activity Score 28-joint count C-reactive protein (DAS28(CRP))>3.2) were randomised 2:1 to CZP (200 mg every 2 weeks (Q2W)) plus bimekizumab (240 mg loading dose then 120 mg Q2W) or CZP plus placebo. The primary efficacy and safety variables were change in DAS28(CRP) between Weeks 8 and 20 and incidence of treatment-emergent adverse events (TEAEs). RESULTS: Of 159 patients enrolled, 79 had IR at Week 8 and were randomised to CZP plus bimekizumab (n=52) or CZP plus placebo (n=27). At Week 20, there was a greater reduction in DAS28(CRP) in the CZP-IR plus bimekizumab group compared with the CZP-IR plus placebo group (99.4% posterior probability). The most frequent TEAEs were infections and infestations (CZP plus bimekizumab, 50.0% (26/52); CZP plus placebo, 22.2% (6/27)). CONCLUSIONS: PoC was confirmed based on the rapid decrease in disease activity achieved with 12 weeks of CZP plus bimekizumab. No unexpected or new safety signals were identified when neutralising IL-17A and IL-17F in patients with RA concomitantly treated with CZP, but the rate of TEAEs was higher with dual inhibition.
引用
- Glatt S, Taylor PC, McInnes IB, et al. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Ann Rheum Dis. 2019. PMID: 31177099. doi:10.1136/annrheumdis-2018-214943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。